SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Disciplined Investing, especially the NAIC way -- Ignore unavailable to you. Want to Upgrade?


To: The Philosopher who wrote (332)6/21/2002 1:09:52 PM
From: - with a K  Read Replies (1) | Respond to of 469
 
Hi Christopher,

I haven't looked at Amgen but would like to someday. KG looks interesting to me from this list, and it is selling off today.

Snapshot: "Vertically integrated pharmaceutical company that manufactures, markets and sells branded prescription pharmaceutical products to general/family practitioners and internal medicine physicians and cardiologists."

Today's news: "King Pharms selling off on Levoxyl concerns (KG) 21.17 -3.63: Stock has been under heavy selling pressure after JP Morgan issued a note before the open saying that the firm is now concerned that generic Levoxyl is more of a threat than previously anticipated; thinks the mkt is unaware of the fact that Levoxyl is already listed as a "reference drug", and expects ambiguity around Levoxyl generics to continue until a new patent is issued or a generic is actually launched; cuts price target to $35 from $55."

I show KG as having low debt, a low PEG, high margins (27% net!) and I see that SmartMoney recently named KG as No. 1 in its list of "Lean, Mean, Future Profit Machines" out of 8,000 companies.

Using Quicken's intrinsic value calculator and an EPS growth rate of only 15% vs. consensus of 22%, it comes out undervalued. Quicken also shows it in the top quintile for all fundamentals!

Haven't done a SSG though but the earnings history looks OK at this point....